{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:15:52Z","timestamp":1789193752239,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171277"],"award-info":[{"award-number":["82171277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171338"],"award-info":[{"award-number":["82171338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young and Technological Talents (Level Three) in Tianjin","award":["QN20230344"],"award-info":[{"award-number":["QN20230344"]}]},{"name":"the Tianjin Health Research Project","award":["TjWJ2022QN008"],"award-info":[{"award-number":["TjWJ2022QN008"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["Tianjin Key Medical Discipline (Specialty) Construction Project"],"award-info":[{"award-number":["Tianjin Key Medical Discipline (Specialty) Construction Project"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10072-025-08046-5","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T07:41:54Z","timestamp":1739518914000},"page":"2759-2764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study"],"prefix":"10.1007","volume":"46","author":[{"given":"Yuan","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-0648","authenticated-orcid":false,"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"8046_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF (2022) Neuromyelitis Optica Spectrum Disorder. N Engl J Med 387:631\u2013639. https:\/\/doi.org\/10.1056\/NEJMra1904655","journal-title":"N Engl J Med"},{"key":"8046_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG (2021) Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Reviews Neurol 17:759\u2013773. https:\/\/doi.org\/10.1038\/s41582-021-00568-8","journal-title":"Nat Reviews Neurol"},{"key":"8046_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis Optica. Nat Reviews Disease Primers 6:85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9","journal-title":"Nat Reviews Disease Primers"},{"key":"8046_CR4","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.lanwpc.2020.100021","volume":"2","author":"DC Tian","year":"2020","unstructured":"Tian DC, Li Z, Yuan M, Zhang C, Gu H, Wang Y, Shi FD (2020) Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study. Lancet Reg Health Western Pac 2:100021. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100021","journal-title":"Lancet Reg Health Western Pac"},{"key":"8046_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, Jacob A, Kira JI, Leite MI, Marignier R et al (2021) Worldwide Incidence and Prevalence of Neuromyelitis Optica: a systematic review. Neurology 96:59\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000011153","journal-title":"Neurology"},{"key":"8046_CR6","doi-asserted-by":"publisher","unstructured":"Beekman J, Keisler A, Pedraza O, Haramura M, Gianella-Borradori A, Katz E, Ratchford JN, Barron G, Cook LJ, Behne JM et al (2019) Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurology(R) neuroimmunology & neuroinflammation 6, e580. https:\/\/doi.org\/10.1212\/NXI.0000000000000580","DOI":"10.1212\/NXI.0000000000000580"},{"key":"8046_CR7","doi-asserted-by":"publisher","unstructured":"Carnero Contentti E, Correale J (2021) Neuromyelitis Optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflamm 18. https:\/\/doi.org\/10.1186\/s12974-021-02249-1","DOI":"10.1186\/s12974-021-02249-1"},{"key":"8046_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M et al (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19:391\u2013401. https:\/\/doi.org\/10.1016\/S1474-4422(20)30070-3","journal-title":"Lancet Neurol"},{"key":"8046_CR9","doi-asserted-by":"publisher","first-page":"101920","DOI":"10.1016\/j.msard.2019.101920","volume":"39","author":"I Lotan","year":"2020","unstructured":"Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I (2020) Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Multiple Scler Relat Disorders 39:101920. https:\/\/doi.org\/10.1016\/j.msard.2019.101920","journal-title":"Multiple Scler Relat Disorders"},{"key":"8046_CR10","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H et al (2019) Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381:2114\u20132124. https:\/\/doi.org\/10.1056\/NEJMoa1901747","journal-title":"N Engl J Med"},{"key":"8046_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P et al (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19:402\u2013412. https:\/\/doi.org\/10.1016\/S1474-4422(20)30078-8","journal-title":"Lancet Neurol"},{"key":"8046_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Havrdova K, Spelman E, T., et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19:307\u2013316. https:\/\/doi.org\/10.1016\/S1474-4422(20)30067-3","journal-title":"Lancet Neurol"},{"key":"8046_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning N, Liu Q, Shao ZH et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81:710\u2013713. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a1aac7","journal-title":"Neurology"},{"key":"8046_CR14","doi-asserted-by":"publisher","first-page":"578285","DOI":"10.1016\/j.jneuroim.2024.578285","volume":"387","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu R, Gao B, Li T, Wang H, Song T, Ma Y, Xu W, Liu Y, Zhang X et al (2024) Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder. J Neuroimmunol 387:578285. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578285","journal-title":"J Neuroimmunol"},{"key":"8046_CR15","doi-asserted-by":"publisher","first-page":"660230","DOI":"10.3389\/fimmu.2021.660230","volume":"12","author":"C Du","year":"2021","unstructured":"Du C, Zeng P, Han JR, Zhang TX, Jia D, Shi FD, Zhang C (2021) Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder. Front Immunol 12:660230. https:\/\/doi.org\/10.3389\/fimmu.2021.660230","journal-title":"Front Immunol"},{"key":"8046_CR16","doi-asserted-by":"publisher","first-page":"102940","DOI":"10.1016\/j.msard.2021.102940","volume":"52","author":"L Du","year":"2021","unstructured":"Du L, Chang H, Xu W, Zhang X, Yin L (2021) Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders. Multiple Scler Relat Disorders 52:102940. https:\/\/doi.org\/10.1016\/j.msard.2021.102940","journal-title":"Multiple Scler Relat Disorders"},{"key":"8046_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000494976","volume":"25","author":"Y Wei","year":"2018","unstructured":"Wei Y, Chang H, Li X, Wang H, Du L, Zhou H, Xu W, Ma Y, Yin L, Zhang X (2018) Cytokines and tissue damage biomarkers in First-Onset Neuromyelitis Optica Spectrum disorders: significance of Interleukin-6. Neuroimmunomodulation 25:215\u2013224. https:\/\/doi.org\/10.1159\/000494976","journal-title":"Neuroimmunomodulation"},{"key":"8046_CR18","doi-asserted-by":"publisher","unstructured":"Kong BS, Kim Y, Kim GY, Hyun JW, Kim SH, Jeong A, Kim HJ (2017) Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. J Neuroinflamm 14. https:\/\/doi.org\/10.1186\/s12974-017-0961-z","DOI":"10.1186\/s12974-017-0961-z"},{"key":"8046_CR19","doi-asserted-by":"publisher","unstructured":"Matsuoka T, Araki M, Lin Y, Okamoto T, Gold R, Chihara N, Sato W, Kimura A, Tachimori H, Miyamoto K et al (2024) Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder. Neurology(R) neuroimmunology & neuroinflammation 11. https:\/\/doi.org\/10.1212\/NXI.0000000000200173","DOI":"10.1212\/NXI.0000000000200173"},{"key":"8046_CR20","doi-asserted-by":"publisher","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Konnecke H, Schippling S, Rommer PS, Kornek B et al (2022) Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology(R) neuroimmunology & neuroinflammation 9. https:\/\/doi.org\/10.1212\/NXI.0000000000001100","DOI":"10.1212\/NXI.0000000000001100"},{"key":"8046_CR21","doi-asserted-by":"publisher","unstructured":"Takeshita Y, Fujikawa S, Serizawa K, Fujisawa M, Matsuo K, Nemoto J, Shimizu F, Sano Y, Tomizawa-Shinohara H, Miyake S et al (2021) New BBB Model reveals that IL-6 Blockade suppressed the BBB disorder, preventing onset of NMOSD. Neurology(R) Neuroimmunol Neuroinflammation 8. https:\/\/doi.org\/10.1212\/NXI.0000000000001076","DOI":"10.1212\/NXI.0000000000001076"},{"key":"8046_CR22","doi-asserted-by":"publisher","unstructured":"Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Budingen HV, Klingelschmitt G et al (2023) Long-term efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder from SAkuraSky and SAkuraStar. Neurology(R) Neuroimmunol Neuroinflammation 10. https:\/\/doi.org\/10.1212\/NXI.0000000000200071","DOI":"10.1212\/NXI.0000000000200071"},{"key":"8046_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M et al (2020) Safety and efficacy of Rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306. https:\/\/doi.org\/10.1016\/S1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"8046_CR24","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","volume":"99","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, Fitzgerald KC, Levy M, Pardo CA, Newsome SD, Mowry EM, Calabresi PA, Sotirchos ES (2022) Long-term effectiveness and safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG antibody disease. Neurology 99:e2504\u2013e2516. https:\/\/doi.org\/10.1212\/WNL.0000000000201260","journal-title":"Neurology"},{"key":"8046_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/jnnp-2022-330714","volume":"94","author":"SY Park","year":"2023","unstructured":"Park SY, Kwon YN, Kim S, Kim SH, Kim JK, Kim JS, Nam TS, Min YG, Park KS, Park JS et al (2023) Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum. J Neurol Neurosurg Psychiatry 94:800\u2013805. https:\/\/doi.org\/10.1136\/jnnp-2022-330714","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8046_CR26","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","volume":"101","author":"S Demuth","year":"2023","unstructured":"Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, Cohen M, Deschamps R, Durand-Dubief F, Maillart E et al (2023) Rituximab de-escalation in patients with Neuromyelitis Optica Spectrum Disorder. Neurology 101:e438\u2013e450. https:\/\/doi.org\/10.1212\/WNL.0000000000207443","journal-title":"Neurology"},{"key":"8046_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","volume":"117","author":"M Zhang","year":"2017","unstructured":"Zhang M, Zhang C, Bai P, Xue H, Wang G (2017) Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg 117:695\u2013702. https:\/\/doi.org\/10.1007\/s13760-017-0795-6","journal-title":"Acta Neurol Belg"},{"key":"8046_CR28","doi-asserted-by":"publisher","first-page":"1148632","DOI":"10.3389\/fimmu.2023.1148632","volume":"14","author":"D Zhao","year":"2023","unstructured":"Zhao D, Ren K, Lu J, Liu Z, Li Z, Wu J, Xu Z, Wu S, Lei T, Ma C et al (2023) Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study. Front Immunol 14:1148632. https:\/\/doi.org\/10.3389\/fimmu.2023.1148632","journal-title":"Front Immunol"},{"key":"8046_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","volume":"317","author":"J Lin","year":"2018","unstructured":"Lin J, Li X, Xue B, Tong Q, Chen Z, Zhu W, Li J, Xia J (2018) Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. J Neuroimmunol 317:1\u20134. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.02.004","journal-title":"J Neuroimmunol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08046-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:24:36Z","timestamp":1747376676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08046-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["8046"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08046-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Committee on Medical Ethics of Tianjin Medical University General Hospital, code IRB2017-YX-009. Participants provided written informed consent before beginning the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}